Currnt | Private vs. Public, which is the Best Financial Modality for bringing new Synthetic Biology Pharmaceuticals to the market?

Latest questions:

2 What is the value of increased automation in the Data Center and NOC?

2 What is the Real Difference between Supply-Side and Demand-Side Economics?

4 Covid-19 and Higher Education

4 The role of RFID and Digital Marketing

5 Digital transformation strategy

3 Blockchain for New Media, Content Rights and Creators

3 How will Artificial Intelligence affect the future of work?

2 Are electronic log books the answer for truck drivers?

2 What to expect from community anchor institutions

4 Opportunity or Scam?

Hot questions:

60 Profit vs. Customer Satisfaction

46 Obesity Prevention

34 Will Bitcoin hit $1M by the end of 2020?

32 Quality of Internal Innovation - low or really low

31 Sales Growth Strategy

29 Focus Groups - Dead or Alive?

29 How FDA is preparing for wave of change to personalized medicine?

28 KPIs in Supply chain Management

23 How technology will impact aging population in the future?

22 Amazon & Whole Foods

BACK TO QUESTIONS

Private vs. Public, which is the Best Financial Modality for bringing new Synthetic Biology Pharmaceuticals to the market?

1605 views

Would "1000 Private" companies be more likely to bring new Synthetic Biology Pharmaceuticals instead of publicly funded ones, and why?

Cort M. Johns, PhD-HSG
80 months ago

1 answer

The strategies followed by key players in this market present a clear understanding about the intensity of concentration they are giving to a specific business segment. Strategic analysis of the companies reveals that most of the companies are concentrating on agreements followed by product launch for the expansion of their business. The agreements among the companies would enhance their operations and services. Most of the agreements were related to development of product for chemical industries, followed biofuels and synthetic genes industries. Product launches were adopted by the companies to diversify their products and explore new areas of applications. Companies adopted strategies to launch new products to diversify its approach in the chemical industry and pharmaceuticals. Companies also adopted strategies such as collaboration, joint venture and acquisition for the expansion of their business. These strategies resulted in the advancement of the technology and diversification of the products in the untapped areas. These strategies were adopted by the companies to diversify their business in the industries such as pharmaceuticals, synthetic genes, biofuels and chemicals. In this scenario is very hard thinking that the public sector could be competitive.

Pietro Carotenuto
80 months ago

Thank you for your interesting and informative response Pietro. Unfortunately, The Covetit Board did not find my question of sufficient import to include my further participation in this Forum. For the amount of time required to research and provide cogent posts here, a monthly honorarium of $50.00 is tantamount to volunteering ones time. Best wishes for finding informed responses to your posts. - Cort M. 80 months ago

Have some input?

BACK TO QUESTIONS

Latest questions:

Trending questions:

Hot questions:

Private vs. Public, which is the Best Financial Modality for bringing new Synthetic Biology Pharmaceuticals to the market?

1 answer

Have some input?

Thanks for making your first post!

Login to your account

Create your account

Recover password

Linkedin URL

Total Points:

Edit Message